Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Solid Cancers 1Polycythemia Vera 1Neoplasm of Uncertain Malignant Potential 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1

Interventions

Decitabine 4Cyclophosphamide 4ruxolitinib 3fludarabine phosphate 3Filgrastim 3Etoposide 3Topotecan 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2LY2784544 2Cytarabine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1umbralisib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1peginterferon alfa-2a 1nelarabine 1navitoclax 1fresolimumab 1durvalumab 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Polycythemia Vera × peginterferon alfa-2a × Clear all
NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡